CHI3L1 and Alzheimer disease: Moreover, the REIMAGINE-AD and ETHERAL studies have shown that vafidemstat causes reductions in agitation/aggression scales and in cerebrospinal fluid levels of the inflammatory biomarker YKL40 in patients with mild-to-moderate AD (232).